Albany NY, United States: A key drive for Remicade biosimilar market stems from the fact that numerous biological innovative products, including monoclonal antibodies are nearing patent expiries.
Albany NY, United States: A key drive for Remicade biosimilar market stems from the fact that numerous biological innovative products, including monoclonal antibodies (mAbs) are nearing patent expiries. A growing research on developing biosimilars to these is a key trend bolstering the growth prospects. A number of biosimilars to Infliximab (IFX) biological therapy have been approved, notably by the FDA. In the past, IFX was found to be effective in Crohn’s disease (CD) and ulcerative colitis (UC). Particularly, biological therapies including Remicade biosimilar exhibit vast revenue potential for inflammatory bowel disease (IBD). A relentless focus on reducing the overall cost of chronic diseases notably IBD-related healthcare is a key aspect propelling advances in this direction. Great strides have been made in efficacy and safety data, which underpin potential revenue streams in the Remicade biosimilar market. Newer FDA-approved products in the market target patients with ankylosing spondylitis, plaque psoriasis, and psoriatic arthritis.
Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37868
Constant focus on expansion of biosimilar portfolios by globally prominent drug makers is a key trend bolstering the prospects in the Remicade biosimilar market. They are increasingly inclined toward offering affordable biological treatment options especially in oncology. However, developing Remicade biosimilar that have low risk factors particularly from risk for serious infection of opportunistic pathogens is veritable challenge that will anchor more research and development funding worldwide.
Demand for biological products is high for the treatment of a large number of diseases. However, demand for biosimilar products is increasing to lower health care costs. Biosimilar products are derived in reference to biological products and have similar safety, efficacy, purity, and effectiveness when compared to the original products. Biosimilar can be characterized as a sort of biologic item that is profoundly like an as of now FDA approved biologic drug, known as reference drug. Biosimilars are drugs approved by the U.S. FDA and the European Medicine Agency (EMA) and show no clinical and meaningful difference from the reference biological product. These biosimilar products can be approved only for indications which are previously approved for the reference biological product by authorized regulatory bodies.
Request for Covid-19 Impact Analysis: https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=37868
In 1998, the U.S. FDA licensed Remicade (infliximab), a monoclonal antibody originally produced by Janssen Biotech, Inc. and Merck & Co. in partnership. Its primary indication included Crohn’s disease in both adult and pediatric patients. It is also indicated for the treatment of ulcerative colitis, spinal psoriatic arthritis, plague psoriasis, and rheumatic arthritis when given in combination with methotrexate. The U.S. FDA approved biosimilar to Remicade named Inflectra on April 05, 2016. Pfizer launched Inflectra in the market at 15% discount on the original market price of the reference product. However, in April 2017, another biosimilar Renflexis (infliximab-abda), a tumor necrosis factor to Remicade by Samsung Bioepis and Merck & Co., was approved to be launched into the market. It is approved for almost all the indications that were approved under Remicade such as ulcerative colitis, spinal psoriatic arthritis, plague psoriasis, rheumatic arthritis, and ankylosing spondylitis.
Increase in incidence of autoimmune disorders such as rheumatoid arthritis, and psoriasis, patent expiry of branded drugs, and rise in health care costs drive the Remicade biosimilar market. Additionally, faster entry of Biosimilars into the Europe market leads to cost reduction and faster medicines accessibility help to grow this market. However, serious side effects associated with the drug could lead to fatality. This factor restraints the market.
Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=37868
The global Remicade biosimilar market can be segmented based on approved indication and region. In terms of approved indication, the market can be categorized into ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ankylosing spondylitis. Ulcerative colitis and rheumatoid arthritis show higher demand due to increase in number of cases of these diseases. Psoriasis also increase market demand owing to increase in the cases of autoimmune diseases. Based on region, the global Remicade biosimilar market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the market owing to high incidence of autoimmune diseases and increase in geriatric population. Europe is the second largest market for Remicade. Easy access to biosimilar medications in the region drives the market. India, southeast Asia, and China are emerging markets for biosimilar medicines because of changing lifestyle and increase in healthcare facilities in these regions.
Key players in the global Remicade biosimilar market comprise Alvogen, Napp Pharmaceuticals, Janssen Biotech, Inc., Merck &Co., Pfizer, Inc., Cell Trion, and Nippon Kayaku.
More Trending Reports by Transparency Market Research:
Biosimilar Monoclonal Antibodies Market: Biosimilar monoclonal antibodies can be defined as biological molecules derived from living cells or organisms. These are large complex molecules. Biosimilars are developed after the expiry of patent of approved recombinant drugs, and are also known as biologics.
Herceptin Biosimilar Market: Trastuzumab, sold under the brand Herceptin, is a monoclonal antibody used to treat patients suffering from HER2+ve breast cancer and gastric cancers. It is primarily administered intravenously in cancer patients. Herceptin binds to HER2 receptors on the surface of breast cancer cells and blocks them from receiving growth signals, thereby leading to apoptosis and decrease in mutation of cells.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453